The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.317
Bid: 0.311
Ask: 0.323
Change: 0.0035 (1.12%)
Spread: 0.012 (3.859%)
Open: 0.3135
High: 0.00
Low: 0.00
Prev. Close: 0.3135
IDHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of radiology business in Egyptian market

14 Aug 2018 09:46

RNS Number : 7448X
Integrated Diagnostics Holdings PLC
14 August 2018
 

IDH launches radiology business in fast-growing Egyptian market

 

A strategic expansion that is set to transform IDH's Egyptian operation into a one-stop-shop diagnostics service provider; the investment is planned to have limited impact on cashflows

 

14 August 2018

 

(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Company" or "the Group," IDHC on the London Stock Exchange), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan, and Nigeria, is set to launch a radiology business in Egypt.

 

IDH is building a national brand in Egypt with a service offering highly complementary to its existing pathology-focused medical diagnostics services.

 

"Our expansion into a high-value, adjacent segment of our industry is a milestone in the development of IDH on par with the expansion into Africa that now sees operations in three countries outside Egypt contributing double-digit percentages to our top line," said Dr. Hend El Sherbini, Chief Executive Officer of IDH.

 

"Our market in Egypt is growing in the double digits, and so is our top line. Today, more than 75% of customers surveyed by a third-party research provider indicate a preference for consolidated service offerings that feature both pathology and radiology - and there is significant existing demand for us to capture. Our expectation is that our pathology business will deliver new patients to our radiology business and that, in the fullness of time, having both services under one roof will also drive growth in our pathology test volumes."

 

"Importantly, our expansion into the fragmented radiology market will be powered by the strong relationships between our brands and our millions of customers as well as the physicians who trust us to be part of their diagnostic and treatment plans," El Sherbini noted.

 

Al Borg Scan will offer a full range of radiology services, including but not limited to magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, x-ray, mammograms and cath lab facilities. It will draw on Al Borg's brand equity to position itself as a premium service provider offering the full range of imaging services using the latest technology and highly trained staff. Medical equipment suppliers for the new venture are global brand names including Siemens, Hitachi, GE Healthcare, and Fujifilm. The company will emphasize convenience with the rollout of its mobile app and website and reinforce its high-end brand positioning with a premium facility and atmosphere at each of its branches. The business will be led by a group of the nation's most prominent radiologists with a track record at Egypt's leading hospitals and radiology centers.

 

Up to 70% of the cost of the expansion into radiology is now in place through an EGP 130.5 million, eight-year facility from the Ahli United Bank of Egypt. The facility is ring-fenced to Al Borg with no guarantees from, or recourse on, IDH or any of its other subsidiaries. The balance of the investment is planned to be financed from the operating cashflows of Al Borg.

 

IDH delivered 29% top-line growth in the first quarter of 2018, performing 6.6 million tests (+8% compared to 1Q2017) for 1.7 million patients (+13% year-on-year), underscoring the health of its core business as Egypt recovers from a period of devaluation and high inflation. Nigeria is the company's newest expansion market, making its first contribution to the Group's consolidated revenues in 1Q2018. IDH is expected to announce 1H2018 results on 16 August 2018.

 

 

-Ends-

 

 

About Integrated Diagnostics Holdings

 

IDH is the largest fully integrated private-sector medical diagnostics services provider in Egypt, Jordan, Sudan, and Nigeria, comprehensively offering pathology and molecular diagnostics, genetics testing and basic radiology. IDH's core brands include Al Borg and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Echo-Scan (Nigeria). IDH is listed on the London Stock Exchange (ticker: IDHC) and was founded in 2012 by the merger of Al Borg and Al Mokhtabar, the most established diagnostics services brands in Egypt.

 

 

Contact

Mr. Sherif El-Ghamrawi

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)10 0447 8699 | sherif.elghamrawi@idhcorp.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PRLDMGMRRDZGRZG
Date   Source Headline
30th Apr 20242:13 pmRNSNotice of AGM
4th Apr 20241:55 pmRNSAnnual Financial Report
28th Mar 20247:00 amRNSFinal Results
26th Mar 20249:15 amRNSNotice of Results
18th Jan 20244:03 pmRNSIDH appoints Group CFO, VP and Board Member
16th Nov 20237:00 amRNS3rd Quarter Results
25th Oct 20237:00 amRNSIDH CEO increases stake in the Company
17th Oct 20231:56 pmRNSDirector/PDMR Shareholding
16th Oct 202312:26 pmRNSDirector/PDMR Shareholding
13th Oct 20232:02 pmRNSDirector/PDMR Shareholding
12th Oct 202310:33 amRNSDirector/PDMR Shareholding
11th Oct 202310:45 amRNSDirector/PDMR Shareholding
31st Aug 20237:00 amRNSHalf-year Report
30th Aug 20239:57 amRNSNotice of Results
21st Jun 202311:18 amRNSCFO & Strategic Investment Officer Appointments
14th Jun 20233:01 pmRNSDirector/PDMR Shareholding
1st Jun 20237:00 amRNS1st Quarter Results
30th May 20235:49 pmRNSResult of AGM
4th May 20233:03 pmRNSAnnual Financial Report & Notice of AGM
28th Apr 20234:01 pmRNSDirector/PDMR Shareholding
18th Apr 20233:23 pmRNSDirector/PDMR Shareholding
6th Apr 202311:05 amRNSFinal Results
6th Apr 20237:00 amRNSPreliminary Results
4th Apr 20236:10 pmRNSNotice of Results
21st Feb 20234:35 pmRNSPrice Monitoring Extension
6th Feb 20234:40 pmRNSSecond Price Monitoring Extn
6th Feb 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSIDH to no longer pursue acquisition of IDC stake
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20227:00 amRNS3rd Quarter Results
10th Nov 20221:55 pmRNSNotice of Results
31st Oct 202210:06 amRNSIDH launches Greenfield in KSA with Izhoor
5th Oct 20221:09 pmRNSIDH launches sixth Al-Borg Scan Branch
5th Oct 202212:49 pmRNSAl-Borg Scan obtains ACR Accreditation
12th Sep 20228:23 amRNSHalf-year Report
7th Sep 20224:04 pmRNSNotice of Results
6th Sep 20229:30 amRNSIDC termination; negotiations ongoing
22nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20224:36 pmRNSPrice Monitoring Extension
17th Aug 20224:41 pmRNSSecond Price Monitoring Extn
17th Aug 20224:36 pmRNSPrice Monitoring Extension
16th Aug 20222:09 pmRNSIDH CEO ups stake in the Company
16th Aug 202211:19 amRNSDirector/PDMR Shareholding
15th Aug 20224:41 pmRNSSecond Price Monitoring Extn
15th Aug 20224:36 pmRNSPrice Monitoring Extension
11th Aug 20226:01 pmRNSDirector/PDMR Shareholding
11th Aug 20225:44 pmRNSDirector/PDMR Shareholding
9th Aug 20225:27 pmRNSDirector/PDMR Shareholding
9th Aug 20222:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.